These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16079926)

  • 1. Losartan controlled blood pressure and reduced left ventricular hypertrophy but did not alter arrhythmias in hypertensive men with preserved systolic function.
    Zakynthinos E; Pierrutsakos Ch; Daniil Z; Papadogiannis D
    Angiology; 2005; 56(4):439-49. PubMed ID: 16079926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Losartan reduces left ventricular hypertrophy proportionally to blood pressure reduction in hypertensives, but does not affect diastolic cardiac function.
    Zakynthinos E; Pierutsakos Ch; Konstantinidis K; Zakynthinos S; Papadogiannis D
    Angiology; 2004; 55(6):669-78. PubMed ID: 15547653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.
    Novo S; Abrignani MG; Novo G; Nardi E; Dominguez LJ; Strano A; Barbagallo M
    Am J Hypertens; 2001 Jul; 14(7 Pt 1):637-43. PubMed ID: 11465647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
    Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
    Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients.
    Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H; Suzuki H
    J Cardiovasc Pharmacol; 2004 Mar; 43(3):380-6. PubMed ID: 15076221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
    Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
    Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of losartan on left ventricular mass: a three-year follow-up in elderly hypertensives with myocardial hypertrophy despite successful conventional antihypertensive treatment.
    Moroni C; Tolone S; Lopreiato F; Scrofani AR; Bossini A; Affricano C; Cassone R; Gaudio C
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1323-1328. PubMed ID: 28387895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
    Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
    J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
    Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Arrhythmia risk and noninvasive markers in hypertensive left ventricular hypertrophy].
    Akdeniz B; Güneri S; Badak O; Aslan O; Tamci B
    Anadolu Kardiyol Derg; 2002 Jun; 2(2):121-9; AXVII. PubMed ID: 12134537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
    Ketelhut S; Franz IW; Ketelhut RG
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):385-390. PubMed ID: 30341642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension.
    Pouleur AC; Uno H; Prescott MF; Desai A; Appelbaum E; Lukashevich V; Smith BA; Dahlöf B; Solomon SD;
    J Renin Angiotensin Aldosterone Syst; 2011 Dec; 12(4):483-90. PubMed ID: 21746765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension.
    Sultana R; Sultana N; Rashid A; Rasheed SZ; Ahmed M; Ishaq M; Samad A
    J Ayub Med Coll Abbottabad; 2010; 22(4):155-8. PubMed ID: 22455286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of antihypertensive treatment on left ventricular systolic dyssynchrony in treatment-naïve hypertensive patients.
    Kwon BJ; Jang SW; Choi KY; Kim DB; Cho EJ; Ihm SH; Youn HJ; Rho TH; Kim JH
    Hypertens Res; 2012 Jun; 35(6):661-6. PubMed ID: 22418240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
    Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
    Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
    J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Arterial hypertension, left ventricular hypertrophy and arrhythmias].
    González Maqueda I
    Rev Esp Cardiol; 1991 Nov; 44(9):586-98. PubMed ID: 1723211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myocardial structure and study of arrhythmias during ambulatory electrocardiographic monitoring in mild essential hypertension].
    Pose-Reino A; González-Juanatey JR; Pastor C; Méndez I; Estévez JC; Cabezas-Cerrato J
    Med Clin (Barc); 1996 Jan; 106(1):7-10. PubMed ID: 8750534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.